# TNBC Natural Compounds in Treatment Resistance Research Natural compounds matter in TNBC resistance research because some hit more than one escape route at once. The main themes are **microRNA recovery**, less **EMT**, weaker invasion, and more oxidative pressure on tumour cells. That does not make them proven treatments. It does make them worth tracking when the resistance biology is strong. ### On this page * [Why natural compounds matter here](#why-natural-compounds-matter-here) * [Pterostilbene and miR-205](#pterostilbene-and-mir-205) * [The miR-205 and miR-200 family connection](#the-mir-205-and-mir-200-family-connection) * [Whole blueberries](#whole-blueberries) * [Piperlongumine](#piperlongumine) * [What this means in practice](#what-this-means-in-practice) * [References](#references) * [Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research.md) * [TNBC Off-Label Drugs in Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-off-label-drugs-in-treatment-resistance-research.md) * [Emerging Resistance Strategies](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/emerging-resistance-strategies.md) {% hint style="warning" %} This page is educational only. The evidence here is mainly preclinical. Do not add **pterostilbene**, **piperlongumine**, or other concentrated compounds on the basis of this page without oncology and pharmacy review. {% endhint %} ### Why natural compounds matter here Treatment-resistant TNBC often depends on several escape routes at once. These can include **EMT**, cancer stem-cell persistence, bypass survival signalling, and oxidative-stress handling. Natural compounds are interesting when they appear to push on more than one of those routes together. ### Pterostilbene and miR-205 **Pterostilbene** is a polyphenol found in blueberries. A 2015 Taipei Medical University study, [*Pterostilbene Inhibits Triple-Negative Breast Cancer Metastasis via miR-205 Upregulation and Src Suppression*](https://pubmed.ncbi.nlm.nih.gov/25792283/), tested pterostilbene in **MDA-MB-231** and **Hs578t** TNBC cell lines and in **NOD/SCID** mouse tumour models. At concentrations around **10 µM**, pterostilbene significantly increased **miR-205**. That directly reduced expression of the proto-oncogene **Src**. Downstream, it suppressed the **Src/FAK** signalling axis that drives TNBC invasion and metastasis. The EMT fingerprint was also clear. **E-cadherin** increased. The mesenchymal markers **Snail**, **Slug**, **vimentin**, and **ZEB1** decreased. In the mouse model, both tumour growth and metastasis were suppressed. A 2024 review in *Cancer Letters*, [*MicroRNAs in TNBC chemo-resistance review*](https://www.sciencedirect.com/science/article/pii/S1040842824002592), highlighted pterostilbene and **piperlongumine** among the leading natural compounds modifying **miR-205** in TNBC. This is promising and mechanistically grounded preclinical work. It is not a proven clinical anti-resistance strategy. Human bioavailability at these experimental exposures remains an open question. ### The miR-205 and miR-200 family connection The pterostilbene findings sit inside a broader and well-supported research area. The **miR-200 family** and **miR-205** are consistently low in aggressive, treatment-resistant TNBC. When researchers restore them in model systems, they repeatedly see: * less **EMT** * less migration and invasion * better chemotherapy sensitivity This is now a credible mechanistic target. The main barrier is still human translation. For a broader overview, see [*miRNAs in triple-negative breast cancer: promising biomarkers and therapeutic targets*](https://pmc.ncbi.nlm.nih.gov/articles/PMC11268089/). ### Whole blueberries The blueberry literature is stronger than most whole-food oncology literature in TNBC. A 2013 *Journal of Nutrition* paper, [*Whole Blueberry Powder Inhibits Metastasis of Triple-Negative Breast Cancer via Specific Cytokine-Driven Pathways*](https://pubmed.ncbi.nlm.nih.gov/24364759/), fed **MDA-MB-231** tumour-bearing mice a diet containing **5% whole blueberry powder** alongside a high-fat Western diet. Blueberry-fed mice developed smaller tumours. They also had less ulceration and less lymph-node metastasis. The study reported shifts in cytokine signalling that pointed toward the inflammatory tumour microenvironment as a key target. A 2021 follow-up report, [*Whole Blueberry Powder Modulates the Growth and Metastasis of MDA-MB-231 Triple-Negative Breast Cancer*](https://healthprofessionals.blueberry.org/research/whole-blueberry-powder-modulates-the-growth-and-metastasis-of-mda-mb-231-triple-negative-breast-cancer/), extended that pattern. It reported **70% fewer liver metastases** and **25% fewer lymph-node metastases** in the **5% blueberry-fed** mice compared with controls. The microRNA picture was filled in further by a 2021 *Antioxidants* paper, [*Polyphenol-Enriched Blueberry Preparation Controls Breast Cancer Stem Cells by Targeting FOXO1 and miR-145*](https://pmc.ncbi.nlm.nih.gov/articles/PMC8304479/). In **4T1** and **MDA-MB-231** TNBC cell lines, polyphenol-enriched blueberry preparation significantly increased tumour-suppressor **miR-145** and lowered oncogenic **miR-210**. The rise in **miR-145** was linked to suppression of **PI3K/AKT** and **STAT3** signalling. Those are two of the core bypass-survival routes that keep showing up in chemotherapy resistance. The same study also linked the blueberry preparation to reduced **N-RAS** signalling. Whole blueberries are best viewed as a food-level, low-risk adjunctive idea. They are not a treatment. This is still preclinical evidence. Even so, it is one of the more consistent whole-food evidence findings in TNBC. It also has a plausible mechanistic link to the resistance pathways discussed across this section. {% hint style="info" %} **How to think about whole blueberries** Whole blueberries are a low-risk, nutrient-dense food for most people. They are not known to create the kind of interaction burden that concentrated supplement extracts can. For many readers, a generous daily serving of dried powdered, fresh, or frozen blueberries is a reasonable food-first choice to discuss with the oncology team or dietitian. {% endhint %} {% hint style="warning" %} **Whole food is not the same as a supplement** Eating blueberries is very different from taking a concentrated **pterostilbene** supplement. Supplement dosing, timing around chemotherapy, and interaction questions need a separate discussion with the care team. {% endhint %} ### Piperlongumine **Piperlongumine** enters the conversation from a slightly different angle. It appears to increase stress inside cancer cells, weaken antioxidant defences, and push TNBC cells away from treatment-escape biology. That is why it keeps coming up in anti-resistance discussions. The overlap is functional, not identical. Researchers are interested because the downstream effects may include: * less **EMT** pressure * less invasive behaviour * more treatment sensitivity Its main "super power" appears to be oxidative-stress pressure. That is one reason it keeps drawing attention in treatment-resistance and cancer-stem-cell discussions. For more on that angle, see the [Piperlongumine in Oncology blog article](https://myhealingcommunity.com/piperlongumine-inhibits-antioxidants/). {% hint style="warning" %} **Why full disclosure matters before adding piperlongumine** Piperlongumine has been reported to inhibit key drug-handling enzymes in the liver and intestine, including parts of the **CYP450** and **UGT** systems. These pathways help break down and clear many drugs and natural compounds. If they are inhibited, absorption and bioavailability can rise. Blood levels can increase. Effects can also last longer than expected. That is why **piperlongumine** should not be added to an active treatment plan or a cancer-stem-cell-targeted protocol without oncology and pharmacy review. For the wider interaction logic, also see [Drug Metabolism & Supplement Interactions](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/drug-metabolism-and-supplement-interactions.md). {% endhint %} ### What this means in practice These compounds are still research leads. They are not validated TNBC treatments. The main reason they matter is that they map onto real resistance themes such as **EMT**, survival signalling, microRNA loss, and oxidative-stress defence. Any addition during active treatment needs oncology and pharmacy review first. That matters even more when the compound may affect drug metabolism or widen exposure to other agents already in use. ### References * [MicroRNAs in TNBC chemo-resistance review](https://www.sciencedirect.com/science/article/pii/S1040842824002592) * [Pterostilbene and miR-205 in aggressive TNBC](https://pubmed.ncbi.nlm.nih.gov/25792283/) * [miRNAs in triple-negative breast cancer: promising biomarkers and therapeutic targets](https://pmc.ncbi.nlm.nih.gov/articles/PMC11268089/) * [Blueberry extract and TNBC cell-line study](https://pmc.ncbi.nlm.nih.gov/articles/PMC2862148/) * [Whole blueberry powder in TNBC mouse model](https://pubmed.ncbi.nlm.nih.gov/24364759/) * [Whole Blueberry Powder Modulates the Growth and Metastasis of MDA-MB-231 Triple-Negative Breast Cancer](https://healthprofessionals.blueberry.org/research/whole-blueberry-powder-modulates-the-growth-and-metastasis-of-mda-mb-231-triple-negative-breast-cancer/) * [Blueberries, miR-145, and N-RAS in TNBC](https://pmc.ncbi.nlm.nih.gov/articles/PMC8304479/) * [Piperlongumine in Oncology blog article](https://myhealingcommunity.com/piperlongumine-inhibits-antioxidants/) {% hint style="info" %} ### In this TNBC resistance series * [Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research.md) * [TNBC Natural Compounds in Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-natural-compounds-in-treatment-resistance-research.md) * [TNBC Off-Label Drugs in Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-off-label-drugs-in-treatment-resistance-research.md) * [Emerging Resistance Strategies](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/emerging-resistance-strategies.md) {% endhint %} {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-natural-compounds-in-treatment-resistance-research.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.